China’s medical regulator has approved Brii Biosciences’ antibody combination Covid-19 treatment for adults and adolescents, making it the first therapy of this kind given the green light in the country.
The BRII-196/BRII-198 combination is intended to treat mild Covid-19 and “Types most common” of the disease in patients with high risk of developing severe illness, the National Medical Products Administration said in a statement.
Adults and minors between the ages of 12 and 17 were approved to use this neutralizing antibody mixture.
Brii Biosciences claimed the recent Phase 3 trial of the BRII-196/BRII-198 cocktail has demonstrated “Statistics show a statistically significant drop” of 78% to hospitalization or death in non-hospitalized clinically vulnerable patients.
Two offices are located in China and one in the US. The company applied for an emergency authorization from the US Food and Drug Administration to use the anti-body treatment. Similar cocktails by Eli Lilly, Regeneron Pharmaceuticals, and Eli Lilly have already been approved for the US.
[ad_2]
